Browse > Article
http://dx.doi.org/10.5352/JLS.2010.20.7.1012

Effect of Obesity and Diabetes on Alzheimer's APP Gene Expression in Mouse Adipose Tissues  

Kim, Jin-Woo (Department of Biomedical Science, Catholic University of Daegu)
Lee, Yong-Ho (Department of Biomedical Science, Catholic University of Daegu)
Publication Information
Journal of Life Science / v.20, no.7, 2010 , pp. 1012-1018 More about this Journal
Abstract
The aim of this study was to determine whether Alzheimer's amyloid precursor protein (APP) is dysregulated in adipose tissues of C57BL/6 male mice by high-fat diet (HFD) induced obesity, aging, or streptozotocin (STZ)-induced diabetes. APP mRNA expression was examined by quantitative real-time PCR (QPCR) in subcutaneous (SAT) and epididymal adipose tissues (EAT) from mice in 8 different condition groups. By combining conditions of age (16 weeks/26 weeks of age), diet (normal diet (ND)/high-fat diet), and induction of diabetes (non-diabetic/diabetic), 88 mice were divided into 8 different groups. QPCR demonstrated that APP expression in SAT was significantly increased by about two-fold in HFD-induced obese mice compared to both 16 week-old and 26 week-old mice in the ND group (16 weeks p=0.001; 26 weeks p<0.0001), but no changes in EAT was found. Particular effects of aging on APP gene expression were not observed in either adipose tissue depots. Significantly decreased APP expression was found in SAT in STZ-induced diabetic mice fed on ND or HFD at 16 weeks of age (ND p<0.05; HFD p<0.01). Linear regression analysis demonstrated that APP expression levels correlated with body weight in both the non-diabetic group (R=0.657, p<0.0001, n=39) and the diabetic group (R=0.508, p=<0.0001, n=49), but did not correlate with plasma glucose levels, which suggests that decreased APP expression in STZ-induced diabetic mice is most likely due to weight loss rather than hyperglycemia. These data confirm APP dysregulation by weight changes in humans and suggest a possible role linking midlife obesity with the later development of amyloidogenesis in the brain of older patients with Alzheimer's disease.
Keywords
Amyloid precursor protein; adipose tissue; obesity; diabetes; Alzheimer's disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Lee, Y. H., W. G. Tharp, R. L. Maple, S. Nair, P. A. Permana, and R. E. Pratley. 2008. Amyloid precursor protein expression is upregulated in adipocytes in obesity. Obesity 16, 1493-1500.   DOI   ScienceOn
2 Lee, Y. H., W. G. Tharp, M. Peshavaria, S. Nair, P. A. Permana, and R. E. Pratley. 2006. Overexpression of amyloid precursor protein (APP) in adipose tissue of obese individuals. Obesity, 13, A214.
3 Lee, Y. H., S. Tokraks, R. E. Pratley, C. Bogardus, and P. A. Permana. 2003. Identification of differentially expressed genes in skeletal muscle of non-diabetic insulin-resistant and insulin-sensitive Pima Indians by differential display PCR. Diabetologia 46, 1567-1575.   DOI
4 Lovett, M., D. Goldgaber, P. Ashley, D. R. Cox, D. C. Gajdusek, and C. J. Epstein. 1987. The mouse homolog of the human amyloid beta protein (AD-AP) gene is located on the distal end of mouse chromosome 16: further extension of the homology between human chromosome 21 and mouse chromosome 16. Biochem. Biophys. Res. Commun. 144, 1069-1075.
5 Luchsinger, J. A., M. X. Tang, S. Shea, and R. Mayeux. 2004. Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192.   DOI   ScienceOn
6 Lue, L. F., R. Rydel, E. F. Brigham, L. B. Yang, H. Hampel, G. M., Jr. Murphy, L. Brachova, S. D. Yan, D. G. Walker, Y. Shen, and J. Rogers. 2001. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 35, 72-79.   DOI
7 Galloway, S., L. Jian, R. Johnsen, S. Chew, and J. C. Mamo. 2007. beta-amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J. Nutr. Biochem. 18, 279-284.   DOI
8 Gandy, S. 2005. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest. 115, 1121-1129.
9 Gorospe, E. C. and J. K. Dave. 2007. The risk of dementia with increased body mass index. Age Ageing 36, 23-29.   DOI
10 Gustafson, D., E. Rothenberg, K. Blennow, B. Steen, and I. Skoog. 2003. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch. Intern. Med. 163, 1524-1528.   DOI
11 Hardy, J. and D. J. Selkoe. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.   DOI   ScienceOn
12 Kivipelto, M., T. Ngandu, L. Fratiglioni, M. Viitanen, I. Kareholt, B. Winblad, E. L. Helkala, J. Tuomilehto, H. Soininen, and A. Nissinen. 2005. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch. Neurol. 62, 1556-1560.   DOI
13 Kuusisto, J., K. Koivisto, L. Mykkanen, E. L. Helkala, M. Vanhanen, T. Hanninen, K. Kervinen, Y. A. Kesaniemi, P. J. Riekkinen, and M. Laakso. 1997. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315, 1045-1049.   DOI   ScienceOn
14 Lee, Y. H., J. M. Martin, R. L. Maple, W. G. Tharp, and R. E. Pratley. 2009. Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. Neuroendocrinology 90, 383-390.   DOI   ScienceOn
15 Balakrishnan, K., G. Verdile, P. D. Mehta, J. Beilby, D. Nolan, D. A. Galvao, R. Newton, S. E. Gandy, and R. N. Martins. 2005. Plasma Abeta42 correlates positively with increased body fat in healthy individuals. J. Alzheimers Dis. 8, 269-282.
16 Butterfield, D. A., S. Griffin, G. Munch, and G. M. Pasinetti. 2002. Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimers Dis. 4, 193-201.
17 Combs, C. K., D. E. Johnson, J. C. Karlo, S. B. Cannady, and G. E. Landreth. 2000. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20, 558-567.
18 Craft, S. 2007. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res. 4, 147-152.   DOI
19 Craft, S., E. Peskind, M. W. Schwartz, G. D. Schellenberg, M. Raskind, and D. Jr. Porte. 1998. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.   DOI   ScienceOn
20 Desai, A. K. and G. T. Grossberg. 2005. Diagnosis and treatment of Alzheimer's disease. Neurology 64, S34-S39.   DOI
21 Luchsinger, J. A. and R. Mayeux. 2007. Adiposity and Alzheimer's disease. Curr. Alzheimer Res. 4, 127-134.   DOI
22 White, J. A., A. M. Manelli, K. H. Holmberg, L. J. Van Eldik, and M. J. Ladu. 2005. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis. 18, 459-465.   DOI
23 Whitmer, R. A., E. P. Gunderson, E. Barrett-Connor, C. P., Jr. Quesenberry, and K. Yaffe. 2005. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 330, 1360.   DOI
24 Yamada, T., H. Sasaki, K. Dohura, I. Goto, and Y. Sakaki. 1989. Structure and expression of the alternatively-spliced forms of mRNA for the mouse homolog of Alzheimer's disease amyloid beta protein precursor. Biochem. Biophys. Res. Commun. 158, 906-912.   DOI
25 Yamada, T., H. Sasaki, H. Furuya, T. Miyata, I. Goto, and Y. Sakaki. 1987. Complementary DNA for the mouse homolog of the human amyloid beta protein precursor. Biochem. Biophys. Res. Commun. 149, 665-671.   DOI
26 Zheng, H. and E. H. Koo. 2006. The amyloid precursor protein: beyond amyloid. Mol. Neurodegener. 1, 5.   DOI
27 Nair, S., Y. H. Lee, E. Rousseau, M. Cam, P. A. Tataranni, L. J. Baier, C. Bogardus, and P. A. Permana. 2005. Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians. Diabetologia 48, 1784-1788.   DOI
28 Palmert, M. R., T. E. Golde, M. L. Cohen, D. M. Kovacs, R. E. Tanzi, J. F. Gusella, M. F. Usiak, L. H. Younkin, and S. G. Younkin. 1988. Amyloid protein precursor messenger RNAs: differential expression in Alzheimer's disease. Science 241, 1080-1084.   DOI
29 Peila, R., B. L. Rodriguez, L. R. White, and L. J. Launer. 2004. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 63, 228-233.   DOI   ScienceOn
30 Razay, G., A. Vreugdenhil, and G. Wilcock. 2006. Obesity, abdominal obesity and Alzheimer disease. Dement. Geriatr. Cogn. Disord. 22, 173-176.   DOI
31 Rosengren, A., I. Skoog, D. Gustafson, and L. Wilhelmsen. 2005. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch. Intern. Med. 165, 321-326.   DOI
32 Selkoe, D. J., M. B. Podlisny, C. L. Joachim, E. A. Vickers, G. Lee, L. C. Fritz, and T. Oltersdorf. 1988. Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc. Natl. Acad. Sci. USA 85, 7341-7345.   DOI
33 Small, G. W., P. V. Rabins, P. P. Barry, N. S. Buckholtz, S. T. DeKosky, S. H. Ferris, S. I. Finkel, L. P. Gwyther, Z. S .Khachaturian, B. D. Lebowitz, T. D. McRae, J. C. Morris, F. Oakley, L. S. Schneider, J. E. Streim, T. Sunderland, L. A. Teri, and L. E. Tune. 1997. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. Jama 278, 1363-1371.   DOI
34 Lee, Y. H., S. Nair, E. Rousseau, D. B. Allison, G. P. Page, P. A. Tataranni, C. Bogardus, and P. A. Permana. 2005. Microarray profiling of isolated abdominal subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression of inflammation-related genes. Diabetologia 48, 1776-1783.   DOI